logo-loader
viewActinogen Medical Ltd

Actinogen moves to next stage of Alzheimer's treatment trials

Biotech Actinogen has signed 174 patients for its trial of the drug Xanamem, which may offer a novel new treatment of Alzheimer's disease.

Managing Director Dr Bill Ketelbey says the drug, which treats increased cortisol levels that may decrease cognitive ability, could be "an enormously valuable asset" even though it only treats, rather then cures Alzheimer's.

Quick facts: Actinogen Medical Ltd

Price: 0.02 AUD

ASX:ACW
Market: ASX
Market Cap: $22.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus Ltd 'in good shape' with minimal disruption to supply chain as it...

Admedus Ltd's (ASX:AHZ) Wayne Paterson caught up with Proactive's Andrew Scott to discuss the steps and precautions the firm's taking in the wake of the recent virus outbreak. The company's just announced the hospital discharge of the first patient following its clinical surgical aortic valve...

14 hours, 27 minutes ago

2 min read